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The defects are defined as units that are not members of 
the intended population. Since it was originally developed, 
six sigma has become an element of many total quality 
management (TQM) initiatives. Six sigma is a registered 
service mark and trademark of Motorola, Inc. Motorola 
has reported over US $17 billion in savings from six 
sigma, as of 2006. Other companies using this technique 
are Honeywell International (previously known as Allied 
Signal) and Raytheon and General Electric (introduced by 
Jack Welch). In recent times six sigma has been integrated 
with the TRIZ methodology for problem solving and 
product design.[1-4]
INTRODUCTION
Six sigma is a system of practices originally developed to 
systematically improve processes, by eliminating the defects. 
Pharmaceutics
Six Sigma: Process of Understanding the Control and Capability 
of Ranitidine Hydrochloride Tablet
Chabukswar AR, Jagdale SC, Kuchekar BS, Joshi VD1, Deshmukh GR1, 
Kothawade HS, Kuckekar AB, Lokhande PD2 
MAEER’s Maharashtra Institute of Pharmacy, MIT Campus, Paud Road, Kothrud, Pune – 411 038, 
1Department of Production, Glaxo Smith Kline Pharmaceuticals Ltd., Ambad, Nashik – 422 010, 
2Department of Chemistry, University of Pune, Pune, Maharashtra, India 
Address for correspondence: Dr. Swati Jagdale; E-mail: jagdaleswati@rediffmail.com
ABSTRACT
The process of understanding the control and capability (PUCC) is an iterative closed loop process for continuous 
improvement. It covers the DMAIC toolkit in its three phases. PUCC is an iterative approach that rotates between 
the three pillars of the process of understanding, process control, and process capability, with each iteration 
resulting in a more capable and robust process. It is rightly said that being at the top is a marathon and not a 
sprint. The objective of the six sigma study of Ranitidine hydrochloride tablets is to achieve perfection in tablet 
manufacturing by reviewing the present robust manufacturing process, to find out ways to improve and modify 
the process, which will yield tablets that are defect-free and will give more customer satisfaction. The application 
of six sigma led to an improved process capability, due to the improved sigma level of the process from 1.5 to 
4, a higher yield, due to reduced variation and reduction of thick tablets, reduction in packing line stoppages, 
reduction in re-work by 50%, a more standardized process, with smooth flow and change in coating suspension 
reconstitution level (8%w/w), a huge cost reduction of approximately Rs.90 to 95 lakhs per annum, an improved 
overall efficiency by 30% approximately, and improved overall quality of the product.
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A process that is six sigma (six sigma process quality 
is considered as world class quality) will yield just two 
instances of non-conformances out of every billion 
opportunities, provided there is no shift in the process 
average, and the same process will yield 3.4 instances of 
non-conformances out of every million opportunities with 
an expected shift of 1.5 sigma in the process average. A 
process at four sigma levels (considered average process) 
is expected to yield 63 instances of non-conformances 
for every million opportunities, without a shift in process 
average and 6210 instances of non-conformances with 
a shift in the process average. Contrary to the above, a 
process at the two sigma level is considered a poor quality 
process and is expected to yield 3,08,537 instances of non-
conformances with the shift of 1.5 sigma in the process.[5-7]
The data for the process at different sigma levels are given 
in Table 1. 
Defect values in the Table 1 suggest that as the sigma level 
goes up the defect rate reduces, which means the product 
quality improves. Six sigma, therefore, is a powerful tool 
that can transform defect prone business / industry into an 
organization of perfection. Thus a journey toward sigma 
level means a journey toward making fewer and fewer 
mistakes in everything.
The PUCC framework is explained in Figure 1. The 
framework can be used to manage: current processes, 
process change, and new processes. Eight elements of 
PUCC[8,9] are shown in Figure 2. 
DMAIC
The basic methodology consists of the following five steps:
•  Define the process improvement goals that are consistent 
with customer demands and enterprise strategy. 
•  Measure the current process and collect relevant data 
for future comparison. 
•  Analyze, to verify the relationship and causality of 
factors. Determine what the relationship is, and attempt 
to ensure that all factors have been considered. 
•  Improve or optimize the process based on the analysis, 
using techniques such as the design of the experiments. 
•  Control, to ensure that any variances are corrected 
before they result in defects. Set up pilot runs to 
establish process capability, transition to production, 
and thereafter continuously measure the process and 
its capability.[10-12]
EXPERIMENTAL
Focus methodology
PUCC stands for three phases, process of understanding, 
Table 1: Sigma Table
Sigma Defects per million Yield
6 3.4 99.9997%
5 233.0 99.977
4 6.210.0 99.379
3 66.807.0 93.32
2.5 158.655.0 84.1
2 308.538.0 69.150.0
1.5 500.000.0 50.0
1.4 539.828.0 46.0
1.3 579.260 42.1
1.2 617.911.0 38.2
1.1 655.422.0 34.5
1.0 691.462.0 30.9
0.5 841.345.0 15.9
0.0 933.133.0 6.7
Figure 1: Process capability, control, and understanding framework Figure 2: PUCC, eight elements
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Six sigma
process control, and process capability. These three phases 
cover the DMAIC methodology of six sigma. Instead of 
carrying the project in the phases of PUCC, the project 
was covered by the DMAIC method.[13]
Ranitidine hydrochloride production falls in the following 
stages: Weighing and blending, Compression, Coating, 
and Packing.
Forty batches from NL461 – NL500 were monitored 
throughout these four stages, and enormous data was 
collected, to cover the measure phase of DMAIC.
The data collected was then analyzed using STATISTICA, 
MINITAB 14 (STATISTICAL PACKAGES), and 
MICROSOFT EXCEL.
On completion of the analysis phase, the improved phase 
is initiated, and then the action plan for the control phase 
of DMAIC is designed.
Define
The process improvement goals are consistent with 
customer demands and the enterprise strategy. The 
complete process of manufacturing is defined in terms 
of its various process flow diagrams; the definition of 
the problem must be stated in this step. Process capability 
parameters are defined and are critical to the customer and 
to the quality parameters that are defined.
Ranitidine hydrochloride (RHCL) tablet manufacturing 
is monitored for a long run, up to 35 batches, with 
data regarding the characterization of raw materials, 
comparability study of alternative sources of raw materials, 
manufacturing process such as blending, compression, 
and packing, packing material characterization, packing 
line efficiency, and packing line yields. Data has to be 
collected and treated statistically, to study the trend analysis 
and define most of the contributing variables in the 
process variations. The present Sigma level of the overall 
manufacturing process is between 1.5 and 2.5, and the 
target Sigma value is 4.
Baseline of manufacturing process is defined using 
the following tools
The Ranitidine hydrochloride Process Capability Parameters 
are, Proposed CTQ Trait, Process Map of RHCL tablets, 
[Figure 3], Flow diagram for parameters affecting the 
process, Process flow diagram for RHCL tablets, input 
process output (IPO) diagram for blending process, IPO 
diagram for compression process, blending parameters, 
data required, correlation analysis, variable factor analysis, 
multiple variable graphs, Pareto charts for variables, line 
plots, and trend plots. 
RHCL process capability parameters
Critical to Customer (CTC): Defects that would make 
the customer question the quality or effectiveness of the 
product.[14] 
Proposed CTC trait
Color (uniformity, right color) legibility of print / 
embossing, broken / chipped tablets, thick or thin tablets, 
efficacy, shape.[15]
•  Critical to Quality (CTQ): Defects that would cause a 
batch rejection, batch re-work or FDA action. 
•  Critical to Process (CTP); an item that if not held 
within a certain range as determined through process 
development would cause out-of-specification   
results.[16]
Batch reconciliation in dispensing (per raw material), 
blending time parameters met, blending yield, tablet weights 
(individual, average), tablet thickness, tablet hardness 
(individual, average), tablet friability, tablet disintegration 
time, tablet shape, tablet size, debossing, foreign product 
/ material, uncoated tablet, broken tablet, compression 
accountability, compression yield, QC assay, equilibrium 
relative humidity, press speed, pre-compression force, main 
compression force, blending yield, blending accountability, 
blending LOD, and tablet assay.
Measure
Evaluation of  granule[17]
Tables 2 and 3 indicate data for raw material and blending. 
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Table 2: Data for raw materials
B.No. rr. no. RHCL  
net wt
Assay 
Value  of 
RHCL
Bulk 
density
Tap Den 
sity
Carr 
index
hour rr no. MCCP 
NET 
weight
Bulk  Den 
sity
Tap 
density
Carr 
index
Hausner 
ratio
nl461 6272 168.9 148.1 0.67 0.74 9.5 1.10 6114 129.7 0.29 0.38 23.7 1.31
nl462 6272 168.9 152.1 0.67 0.74 9.5 1.10 6114 129.8 0.29 0.38 23.7 1.31
nl 465 6272 168.8 149.7 0.67 0.74 9.5 1.10 6114 129.8 0.29 0.38 23.7 1.31
nl 466 6272 168.8 146.5 0.67 0.74 9.5 1.10 6114 129.5 0.29 0.38 23.7 1.31
nl 467  6273 168.8 149.4 0.67 0.74 9.5 1.10 6114 130.05 0.29 0.38 23.7 1.31
nl468 6273 168.8 149.9 0.67 0.74 9.5 1.10 6114 130.4 0.29 0.38 23.7 1.31
nl 469 6273 168.8 146.4 0.67 0.74 9.5 1.10 6114 130.9 0.29 0.38 23.7 1.31
nl 470 6273 168.6 147 0.67 0.74 9.5 1.10 6114 130.9 0.29 0.38 23.7 1.31
nl 471 6273 168.9 150.7 0.67 0.74 9.5 1.10 6114 130.33 0.29 0.38 23.7 1.31
nl 472 6273 168.7 147.8 0.67 0.74 9.5 1.10 6114 130.7 0.3 0.38 21.1 1.27
nl 473 6273 169.4 150.1 0.67 0.74 9.5 1.10 6114 130.4 0.3 0.38 21.1 1.27
nl 474 6274 169.4 151.9 0.67 0.74 9.5 1.10 6114 130.3 0.3 0.38 21.1 1.27
nl475 6274 169.4 151.6 0.67 0.74 9.5 1.10 6115 130.63 0.3 0.38 21.1 1.27
nl476 6274 169.5 146.3 0.67 0.74 9.5 1.10 6115 130.4 0.3 0.38 21.1 1.27
nl477 6274 169.4 151.7 0.67 0.74 9.5 1.10 6115 130.1 0.3 0.38 21.1 1.27
nl 478 6274 169.6 153.6 0.67 0.74 9.5 1.10 6115 130.2 0.3 0.38 21.1 1.27
nl 480 6275 168.4 150.9 0.66 0.73 9.6 1.11 6115 130.4 0.3 0.38 21.1 1.27
nl 481 6275 168.4 150.9 0.66 0.73 9.6 1.11 6115 130 0.3 0.38 21.1 1.27
nl 482 6275 168.7 151 0.66 0.73 9.6 1.11 6115 130.2 0.3 0.38 21.1 1.27
nl 483 6275 168.7 150.6 0.66 0.73 9.6 1.11 6115 130.3 0.3 0.38 21.1 1.27
nl 484 6274 168.6 146.2 0.67 0.74 9.5 1.10 6757 130.1 0.3 0.4 25.0 1.33
nl 485 6474 168.9 150.9 0.67 0.74 9.5 1.10 6757 130.1 0.3 0.4 25.0 1.33
nl 486 6474 168.9 145.8 0.67 0.74 9.5 1.10 6757 129.9 0.3 0.4 25.0 1.33
nl 487 6474 168.9 150.5 0.67 0.74 9.5 1.10 6757 130.1 0.3 0.4 25.0 1.33
nl 488 6474 169 150.3 0.67 0.74 9.5 1.10 6757 130.5 0.3 0.4 25.0 1.33
nl489 6474 168.9 149.2 0.67 0.74 9.5 1.10 6757 130.8 0.3 0.4 25.0 1.33
nl 490 6475 168.9 149.8 0.67 0.71 5.6 1.06 6757 130 0.3 0.4 25.0 1.33
nl 491 6475 168.6 149.9 0.67 0.71 5.6 1.06 6757 129.9 0.3 0.4 25.0 1.33
nl 492 6475 168.9 154.1 0.67 0.71 5.6 1.06 6757 130.7 0.3 0.4 25.0 1.33
nl 493 6475 169.3 153.4 0.67 0.71 5.6 1.06 6757 130.1 0.3 0.4 25.0 1.33
nl 494 6475 169.2 149.3 0.67 0.71 5.6 1.06 6757 129.7 0.3 0.4 25.0 1.33
nl 495 6475 169 147.7 0.67 0.71 5.6 1.06 6757 130 0.3 0.4 25.0 1.33
n l 496 6475 169 148.5 0.67 0.71 5.6 1.06 6757 130 0.3 0.4 25.0 1.33
nl 497 6475 169.1 153.4 0.67 0.71 5.6 1.06 6757 130.2 0.3 0.4 25.0 1.33
nl 498 6476 169.9 153.3 130.2 0.3 0.4 25.0 1.33
nl 499 6476 169.2 151.2 130 0.3 0.4 25.0 1.33
nl 500 6476 169.2 153.8 130.4 0.3 0.4 25.0 1.33
Evaluation of  tablet[18]
The features evaluated were: Tablet thickness and diameter, 
tablet hardness, friability, uniformity of weight, and 
uniformity of content.
Analyze
Data collected from 38 batches was analyzed on a statistical 
tool called ‘Statistica’.
Data was analyzed for the following phases and in the 
following order:
•  Raw material and blending
•  Compression
•  Coating
•  Packing
Verification of relationships and causality of factors were 
carried out by using various statistical tools.[19-21] What 
the relationship was also determined and an attempt was 
made to ensure that all factors had been considered. (All 
representative figures of each phase mentioned above had 
been attached in the same sequence).
Improve
The process was improved or optimized based on the 
analysis, using techniques like design of experiment[22] 
and so on. With the help of the above analysis done by 
various statistical tools and techniques, various UDEs 
(undesirable effects) were discovered, and the severity 
and causes of these UDES were discussed. Desirability of 
various improvements was checked and certain suggestions 
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should remain in control, that is, they should be sustained. 
An action review is important for that, and this was carried 
out in this phase.
RESULT AND DISCUSSION
Undesirable effects were observed during the analysis of the 
process using different statistical tools. For minimization 
of undesirable effects, various changes in terms of process 
alteration and corrective measures for manual handling of 
the process were made in the process, for making it more 
capable and robust. 
In order to improve process capability, in the following 
stages different parameters are targeted and their exact 
role is discussed.
•  Blending
•  Compression
•  Coating
•  Packing
(All representative figures of each phase mentioned above 
have been attached in the same sequence). 
Blending 
During the blending process, assay variation [Figures 4 
and 5] was observed in the range of 146 – 152. In order 
to overcome this variation, the existing blender had to 
be replaced with a new blender of higher capacity, it was 
validated and a measurement system analysis of the blend 
was performed. 
Particle size distribution of Ranitidine Hydrochloride 
(RHCL) and microcrystalline cellulose (MCCP) was not 
available to manufacturing heads. This had been informed to 
the Manufacturing Department on the browser, for RHCL 
as well as MCCP, from the Quality Assurance Department, 
with the help of the Information Technology Department.
High cycle time for the activity of weighing, sifting, and 
blending was required and more manpower was used in 
this stage for weighing, sifting, and blending. To avoid this, 
load charting of the weighing, sifting, and blending stage 
had to be carried out, for minimization of manpower, 
Recalculation of the cycle time at the installation of the 
new blender was carried out. Parameters for the granule 
evaluation are as shown in Table 4 and Figures 6 and 7. 
Magnesium stearate [Figure 8] distribution in the batch at 
the top, middle, and bottom was also observed. For even 
distribution of magnesium stearate, the angle of repose 
Table 3: Data on Blending
B no. Speed of 
blender in 
rpm
Time for 
rotation in 
minutes
Weight 
after 
blending  
in kgs
Total time 
for blending 
in minutes
Weight  
loss in 
blending  
in kgs
NL 461 24 15 299.45 17:12:15 1.4
NL462 24 15 326.15 16:19:43 1.1
NL 465 24 15 316.8 16:12:21 1.05
NL 466 24 15 299.5 18:40:07 1.025
NL 467 24 15 301.6 16:34:34 -0.5
NL 468 24 15 315.75 16:45:54 2.3
NL 469 24 15 301.2 17:52:45 0.75
NL 470 24 15 300.5 16:07:39 1.25
NL 471 24 15 300.4 19:56:32 1.12
NL 472 24 15 302.75 17:23:34 -1.1
NL 473 24 15 319.5 17:56:03 1.9
NL 474 24 15 327.95 16:49:32 0.7
NL 475 24 15 318.7 16:54:54 1.58
NL 476 24 15 299.8 18:10:02 2.35
NL 477 24 15 299.45 17:10:34 2.3
NL 478 24 15 300.3 16:54:31 1.75
NL480 24 15 318.95 18:59.0 0.6
NL481 24 15 323.7 18:12:21 0.85
NL482 24 15 299.34 16:39:27 1.81
NL483 24 15 299.75 16:50:10 1.5
NL484 24 15 328.85 17:52:10 0.1
NL485 24 15 317.5 17:55:02 2.75
NL486 24 15 299.6 18:16:10 1.45
NL487 24 15 299.9 17:56:03 1.35
NL488 24 15 300.2 16:46:38 1.55
NL489 24 15 299.65 18:13:10 2.3
NL490 24 15 299.95 17:30:30 1.2
NL491 24 15 299.91 17:40:40 0.84
NL492 24 15 300.75 16:30:40 1.1
NL493 24 15 300.05 17:40:50 1.6
NL494 24 15 301.15 18:10:19 1.1
NL495 24 15 322.9 18:07:20 1.85
NK496 24 15 323.75 17:55:33 2.4
NL497 24 15 322.5 17:54:53 1.05
NL498 24 15 326.55 18:05:10 0.8
NL499 24 15 330.15 16:56:10 0.3
NL500 24 15 318.85 17:55:10 1.2
were made for improvements, which were then discussed. 
Subsequently, these improvements would be implemented 
and their impact would be observed on the improvement of 
yield and sigma level. The major U.D.E’s discovered during 
the analysis phase and their suggestion for improvement 
made the process more capable and robust.
Control
All actions taken in the above-mentioned four phases 
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Figure 7: Carr index of granules for three batches in the blending phase
Figure 5: Process capability report of the assay value of RHCL in the 
blending phase
Figure 4: Trend plot for assay value of RHCL in the blending phase
Figure 6: Hausner ratio of granules for three batches in the blending 
phase
Table 4: Data on Granules
Sr. no NL 486 NL 487 NL 490
Bulk 
density
Tapped 
density
Hausner 
ratio
CI Descri-
ption
Bulk 
density
Tapped 
density
Hausner 
ratio
CI Descri-
ption
Bulk 
density
Tapped 
density
Hausner 
ratio
CI Descri-
ption
Top 01 0.55 0.62 1.13 11.3 E 0.54 0.61 1.13 11.5 E 0.54 0.65 1.20 16.9 F
Top 02 0.55 0.61 .11 9.8 E 0.53 0.61 1.15 13,1 G 0.54 0.63 1.17 14.3 G
Top 03 0.55 0.62 1.13 11.3 E 0.53 0.59 1.11 10.2 E 0.54 0.65 1.20 16.9 F
Middle 01 0.54 0.6 1.11 10.0 E 0.54 0.61 1.13 11.5 E 0.54 0.64 1.17 14.3 E
Middle 02 0.54 0.6 1.11 10.0 E 0.54 0.63 1.17 14.3 G 0.57 0.65 1.14 12.3 E
Middle 03 0.54 0.61 1.13 11.5 E 0.54 0.61 1.13 11.5 E 0.56 0.65 1.16 1.16 E
Bottom 01 0.53 0.59 1.11 10.2 E 0.54 0.61 1.13 11.5 E 0.56 0.65 1.16 13.8 E
Bottom 02 0.54 0.61 1.13 11.5 E 0.57 0.630 1.11 9.5 E 0.54 0.65 1.20 16.9 F
Bottom 03 0.54 0.61 1.13 11.5 E 0.55 0.61 1.09 8.3 E 0.54 0.63 1.17 14.3 G
Carr Index Descriptor
5 – 15 Excellent
12 – 16 Good
18 – 21 Fair to passable
23 – 25 Poor
33 – 38 Very poor
 40 Very very poor
studies was carried out at the time of installation of the 
new blender.
Compression
Considerable variation in tablet weight, tablet thickness, 
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and tablet hardness was observed in Table 5, Figures 9 -13. 
In order to solve the variation in the compression stage 
of different machines, data was observed and entered 
simultaneously on a run chart after replacement of a 
punch set. Checking the thickness of the tablets on the 
first two rotations of the machine, every time the machine 
was restarted, and also collection of data on punch height 
was done.
Average U.R (Utilizable Residue) produced per batch was 
3.5%, that led to extra man hours for rework. In order 
to overcome this variation, interlinking the speed of the 
machine and force feeder was done and also inspection of 
Figure 8: Distribution of magnesium stearate in a batch, in the blending 
phase
TOP MID BOTTOM
400
350
300
250
200
150
100
50
0
MG STEARTE DISTRIBUTION IN A BATCH
1
2
3
Table 5: Compression Data 
Compression on CM 26
B. no. m c no Avg. weight
 in gms
Avg. thickness  
in mms
Avg hardness  
Kg/cm2
Friability in 
 %
UR generated 
In kgs
NL 462 cm 26 0.2997 4.52673 4.9 0.203 8.9
NL 465 cm 26 0.3017 4.47627 4.2 0.231 11.23
NL467 cm 26 0.2979 4.46443 4.75 0.197 8.98
NL469 cm 26 0.3023 4.4972 4.95 0.222 12.2
NL471 cm 26 0.3011 4.5111 5.15 0.108 8.67
NL473 cm26 0.3026 4.48853 4.55 0.197 9.08
NL475 cm 26 0.3025 4.438 4.95 0.228 13.9
NL477 cm 26 0.2995 4.40651 5.2 0.26 8.02
NL481 cm 26 0.3003 4.46448 4.55 0.358 9
NL483 cm 26 0.2998 4.45533 4.25 0.311 9
NL485 cm 26 0.3013 4.4815 4.4 0.299 8.552
NL488 cm 26 0.2968 4.4744 4.3 0.268 9.8
NL490 cm 26 0.2957 4.459 4.55 0.299 9.23
NL492 cm 26 0.2997 4.486 4.65 0.292 11.72
NL494 cm 26 0.3021 4.3963 5.2 0.323 9.23
NL496 cm 26 0.2914 4.436 3.15 0.221 10.8
NL498 cm 26 0.299 4.464 4.45 0.244 9.4
NL499 cm 26 0.3005 4.4455 4.3 0.26 12.8
whether the tablets were taken out, each time the machine 
was adjusted or not was checked.
Considerable variation in friability was found and in order 
to solve this variation, monitoring of moisture content was 
done regularly and data was generated for CHEMFILED, 
to compare it with the existing RANQ.
More unaccounted time and minor stoppages were 
observed and to minimize this, Time value mapping of the 
cleaning activity on a daily and weekly basis was done and 
operator attitude and awareness was addressed.
Rotation of the machine operator was observed daily. To 
minimize this, the staff was fixed for a period of two weeks.
Time wasted while the first shift ended (30 minutes closing 
time) and the second shift started (15 minutes starting time) 
was observed. To utilize that time, overlapping between 
these two times were challenged.
The Present Overall Equipment Effectiveness (OEE) is 
28.75%, and 28.30% for Compression machine CM26 and 
CM27 was observed. To improve the Overall Equipment 
Effectiveness (OEE) level up to 45% for CM26 and 
CM27 as a first target, the project had to be taken by the 
manufacturing heads.
Coating
Considerable  cumulative  Spray  rate  variation   
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Figure 9: Trend chart for average weight in the compression phase
Figure 11: Trend chart for average hardness in the compression phase
Figure 10: Trend chart for average thickness in the compression phase
Figure 12: Trend chart for friability in the compression phase
Figure 13: Process capability report of hardness in the compression 
phase
[Tables 6 and 7, Figures 14 and 15] as well as individual 
gun spray rate variation (50 ml – 450 ml) was observed, 
in order to solve this variation, Gun maintenance and 
replacement was done and when required chocking of 
guns to be minimized or eradicated and also gun cleaning 
frequency and its effectiveness to be addressed. 
Considerable variation in the parameters like: inlet air 
temperature, outlet air temperature, inlet air cfm, outlet air 
cfm, tablet bed temperature, and so on were observed. In 
order to minimize these variations, the same parameters 
were kept in PLC for both the coating pan and calibration 
of velocity. The sensor for filter cleaning was done. Also 
standard parameters values were set.
No robust method of measurement was available to 
measure gun distance from tablet bed, In order to solve 
this problem; Collection of data to see the validated results 
was done.
Uneven weight gain while coating was observed and 
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Table 6: Data on coating spray rate
Date Coating pan Nozzle 1 Nozzle 2 Nozzle 3 Nozzle 4 Nozzle 5 Nozzle 6 Total spray Avg. spray Spray time
16 May 4 250 450 450 230 300 50 1430 238.3333 115.3846154
17 May 4 200 375 400 450 200 50 1675 279.1667 98.50746269
18 May 4 150 310 310 250 100 160 1280 213.3333 128.90625
21 May 4 160 400 400 290 200 310 1760 293.3333 93.75
22 May 4 410 130 400 250 410 150 1750 291.6667 94.28571429
23 May 4 120 360 370 210 225 300 1585 264.1667 104.1009464
Table 7: Coating data on pan no. 5
B. no. Coating 
pan no.
Total 
coating 
time
Drying 
time
Tablet 
bed temp.
Cfm of 
inlet air
Cfm of 
outlet air
Inlet air 
temp 
tange set
Inlet air 
temp. 
min 
actual
Inlet air 
temp. 
max 
actual
Outlet 
air temp.
min
Outlet 
air temp.
mix
Spray 
rate
Erh after 
drying
Weight 
gain 
while 
coating
NL466 5 203 53 60.4 4800 8400 62 60 63 50 52 1440 4.6 7
NL469 5 230 72 59 4250 8175 62 63 65 50 53 1430 4.5 3.5
NL471 5 200 50 54 4260 8175 72 73 74 50 53 1430 5.8 6.5
NL475 5 190 40 57 4800 8400 62 58 62 48 52 1710 5.6 5.6
NL477 5 190 42 59 4800 8175 68 72 73 48 50 1710 6.5 6.5
NL481 5 220 60 50 4250 8175 80 69 71 42 45 1434 4.4 6.2
NL483 5 190 42 54.5 4250 8400 75 73 75 45 46 1434 3.5 7
NL486 5 220 53 59 4800 8400 62 61 63 50 53 1620 6.8 4
NL488 5 200 54 58.9 4800 8400 62 60 62 50 53 1620 4.6 8
NL492 5 215 65 59.5 4250 8175 62 62 63 50 53 1220 1.4 17.4
NL494 5 175 35 61 4250 8175 62 63 64 50 53 1220 4.4 4
NL496 5 220 63 60 4250 8175 62 60 62 51 54 1220 5.3 6
NL498 5 230 78 61 4260 8175 62 61 63 49 40 1300 2.3 6
NL500 5 210 55 60 4260 8175 62 60 64 49 52 1300 7.2 8
Figure 15: Process capability report of weight gain while coating on 
pan 4 in the coating phase
Figure 14: Cumulative spray rate variation per day in pan 4 of the 
coating phase
to solve this variation in weight gain, interaction of 
controllable parameter in coating that results in more or less 
weight gain, for e.g. spray rate ,inlet and outlet air temp, inlet 
and outlet air cfm, atomizing air pressure was observed.
Present Overall Equipment Effectiveness (OEE) is 34.48% 
and 23.66% for coating pan4 and coating pan5, respectively. 
In order to improve the Overall Equipment Effectiveness 
(OEE) level up to 50 - 55% for both the pans as a first 
target, the project was taken up by manufacturing heads.
There was need felt to apply Design of experiment (DOE) 
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for change in coating suspension Reconstitution Level. In 
order to carry out the six sigma tool, design of experiment 
(DOE) for change in coating suspension Reconstitution 
Level, a separate project had to be handled. For that an 
STP (Situation, Target, and Plan) was prepared and also a 
trial protocol prepared.
Packing 
The Average Overall Equipment Effectiveness (OEE) of 
packing lines [Table 8, Figure 16] was 40.53% (single shift 
bases), with individual line OEE being: line 1 (39.39217%), 
line 2 (46.18117%), line 3 (39.16551%), line 4 (35.52693), 
and line 6 (42.38882%). 
In order to achieve Overall Equipment Effectiveness 
(OEE) level in the range of 50 - 65% for all the packing 
lines as a first target, the project had to be taken by the 
Packing Department heads.
It has been observed that the Roll change time contributes 
to 25 – 34% of total stoppage time while completing a 
batch. To minimize this time period, the procedure was 
standardized for changing the rolls. Also efforts were made 
by the Engineering. Department to bring automation in 
the process of roll change and the process mapping was 
carried out at least once in a fortnight.
A run time (on a single shift basis of 570 minutes) of 320 
minutes was observed and to increase this run time, the 
stoppages due to machine adjustment, tablet problem, and 
other miscellaneous factors were minimized. Also process 
mapping was carried out once in a month. Mapping of 
micro-stoppages, morning–evening tea breaks, and ground 
level exit was carried out, to minimize unaccounted time, 
and a BRAVO CARD system was implemented, to give 
recognition to the line operator who was providing the 
maximum output in a week.
Figure 16: Cumulative rejection of RHCL in the packing phase
Chabukswar, et al. J Young Pharm. 2011;3(1): 15-25Journal of Young Pharmacists Vol 3 / No 1  25
Loose winding of plane and printed rolls were observed. 
In order to solve this problem, the issue was addressed at 
the time of procurement of the rolls from the supplier.
The average foil rejection per batch was 12 kg and the 
average weight of the defoiled tablets was 6 kg per batch. 
[Figure 16]. To minimize this rejection, the variation 
in tablet thickness, hardness, weight, and coating, was 
reduced, which made the compression and coating stage 
more robust, to produce minimum number of defects. The 
operator attitude and awareness was also addressed, and 
machine issues that led to tablet and foil rejection, were 
taken care of by the Engineering Department.
CONCLUSION
As various UDEs (Undesirable effects) were discovered and 
discussed in the analysis, an improved phase of DMAIC, 
recommendations, and suggestions came about, to make 
the present process more robust against defects, either by 
bringing new steps in the process or by improving the same 
existent current process. This will result in benefits, some 
tangible and some non-tangible.
•  Given here are some value additions from the process 
of RHCL production obtained by the implementing of 
PUCCInstallation of high capacity blender of 1000 kg, 
replacing the current 300 kg blender, thus saving the 
man-hours by 66% (approximately).
•  Introducing high capacity tote-bins of 200 – 300 kgs, 
which would result in reducing the unloading time 
from the blender, coating the pan to one-third. Man 
and material motion would be reduced to one-third. 
Time of loading and unloading of tote-bins, to lifts, and 
to and from the mezzanine floor would be one-third. 
Batch changeover time would be reduced to 33% of 
the current time, and hence, less amount of U.R would 
be generated.
•  OEE improvement for compression, coating, and 
packing stage, which would lead to 30 – 35% increase 
in OEE for RHCL 150 MG tablets production.
•  Set up time reduction for the whole process by 40 – 
50%.
•  Release of 20 – 30% of the manpower.
•  Process waste reduction, both in compression and 
packing by 35%
•  Rework reduction by 50 – 70%.
•  Reduction in packing line stoppages.
•  Improved process capability due to improved sigma 
level.
•  A more standardize process.
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